同种异体人间充质干细胞输注治疗老年衰弱
结果显示1个月内无治疗相关严重不良事件,6个月内无显著供体特异性免疫反应;所有治疗组3个月和6个月6分钟步行距离增加,6个月TNF-α水平下降。
要点
- 1期内无治疗相关严重不良事件,6个月内无显著供体特异性免疫反应
- 所有剂量组6分钟步行距离在3个月和6个月均较基线增加
- 所有剂量组6个月TNF-α水平下降,1亿剂量组多项功能指标改善最佳
核心结论
- 同种异体人间充质干细胞在老年衰弱患者中安全且免疫耐受良好。
- 功能和免疫学指标的改善支持细胞疗法用于衰弱的后续临床开发。
研究设计与样本
- 1期非随机剂量递增研究,纳入老年衰弱患者。
- 主要终点为输注后1个月治疗相关严重不良事件发生率;次要终点为功能疗效域和炎症生物标志物,分别于3个月和6个月测量。
主要发现
- 输注后1个月无治疗相关严重不良事件,前6个月无显著供体特异性免疫反应。
- 2亿细胞组在输注后258天发生1例死亡。
- 所有治疗组6分钟步行距离在3个月(p=.02)和6个月(p=.001)增加。
- 所有治疗组6个月TNF-α水平下降(p<.0001)。
- 1亿细胞组在所有参数中改善最佳(TNF-α除外),1亿和2亿细胞组TNF-α均改善(p=.0001和p=.0001)。
关键数值与推荐
- 主要终点:输注后1个月治疗相关严重不良事件发生率,结果为无。
- 6分钟步行距离:3个月p=.02,6个月p=.001。
- TNF-α:6个月p<.0001;1亿组p=.0001,2亿组p=.0001。
临床怎么用
- 同种异体人间充质干细胞静脉输注在老年衰弱患者中短期安全性和免疫耐受性可接受。
- 1亿细胞剂量与多项功能指标改善相关,可作为后续研究参考。
局限性
- 非随机设计,样本量小(每组n=5),无安慰剂对照。
- 2亿细胞组发生1例死亡,需进一步评估安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cell (allo-hMSC)-based therapy in patients with aging frailty. METHODS: In this nonrandomized, dose-escalation study, patients received a single intravenous infusion of allo-hMSCs: 20-million (n = 5), 100-million (n = 5), or 200-million cells (n = 5). The primary endpoint was incidence of any treatment-emergent serious adverse events measured at 1 month postinfusion. The secondary endpoints were functional efficacy domains and inflammatory biomarkers, measured at 3 and 6 months, respectively. RESULTS: There were no treatment-emergent serious adverse events at 1-month postinfusion or significant donor-specific immune reactions during the first 6 months. There was one death at 258 days postinfusion in the 200-million group. In all treatment groups, 6-minute walk distance increased at 3 months (p = .02) and 6 months (p = .001) and TNF-α levels decreased at 6 months (p < .0001). Overall, the 100-million dose showed the best improvement in all parameters, with the exception of TNF-α, which showed an improvement in both the 100- and 200-million groups (p = .0001 and p = .0001, respectively). The 100-million cell-dose group also showed significant improvements in the physical component of the SF-36 quality of life assessment at all time points relative to baseline. CONCLUSIONS: Allo-hMSCs are safe and immunologically tolerated in aging frailty patients. Improvements in functional and immunologic status suggest that ongoing clinical development of cell-based therapy is warranted for frailty.
引用
- Golpanian S, DiFede DL, Khan A, et al. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28444181. doi:10.1093/gerona/glx056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。